Morton D L, Goodnight J E
Cancer. 1978 Nov;42(5):2224-33. doi: 10.1002/1097-0142(197811)42:5<2224::aid-cncr2820420521>3.0.co;2-f.
This brief review of the more promising clinical trials suggests that immunotherapy is indeed beneficial for selected cancer patients. Because of its limited potency, it should not be used as primary treatment for malignant disease except as local immunotherapy for certain accessible tumors. It is effective for eradication of primary neoplasms of the skin as well as cutaneous metastases of malignant melanoma and breast carcinoma. The most important role for immunotherapy is in combination with other modalities. It may help control occult micrometastases that cause recurrence and death following surgical procedures or irradiation. Results of adjuvant immunotherapy appear promising for malignant melanoma, for carcinoma of the lung, breast, and colon, and for soft-tissue sarcomas. In combination with chemotherapy, immunotherapy appears to prolong remission and survival in acute myelogenous leukemia and in disseminated tumors of the lung and breast. Clearly, immunotherapy is not a panacea for malignant disease, but it could become an important arm in a multimodality attack on cancer.
这篇对更具前景的临床试验的简要综述表明，免疫疗法确实对特定癌症患者有益。由于其效力有限，除了作为某些可触及肿瘤的局部免疫疗法外，不应将其用作恶性疾病的主要治疗方法。它对于根除皮肤原发性肿瘤以及恶性黑色素瘤和乳腺癌的皮肤转移灶有效。免疫疗法最重要的作用是与其他治疗方式联合使用。它可能有助于控制在手术或放疗后导致复发和死亡的隐匿性微转移。辅助免疫疗法对恶性黑色素瘤、肺癌、乳腺癌、结肠癌以及软组织肉瘤的治疗结果似乎很有前景。与化疗联合使用时，免疫疗法似乎能延长急性髓性白血病以及肺和乳腺播散性肿瘤的缓解期和生存期。显然，免疫疗法并非恶性疾病的万灵药，但它可能成为多模式抗癌治疗中的重要手段。
